Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropeginterferon Alfa-2b for MDS/MPN Overlap Syndromes
NCT07468916Phase 2Not yet recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Sep 2026
- Primary completion
- Sep 2031
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ropeginterferon alfa-2b in myelodysplastic/myeloproliferative neoplasm (MDS/MPN) and chronic myelomonocytic leukemia (CMML), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoints: Overall Response Rate up to 24 months and Adverse Events up to 24 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
myelodysplastic/myeloproliferative neoplasm (MDS/MPN)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT07468916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07468916.